Compass Therapeutics, Inc.
NASDAQ:CMPXBiotechnology
-$0.03 today
- Market cap
- $109.26M
- Beta
- 0.74
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.37
Volume 2.90M
Average 7.64M
CMPX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Compass Therapeutics, Inc.NASDAQ: CMPX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$17.95M, compared with -$16.27M a year earlier. Trailing-twelve-month EBITDA was -$67.05M.
Context
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 7 analysts of -$80.47M (-23.8%) for the fiscal year ending Dec 2026, a step up from the -36.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$17.95M-17.0% QoQ
- Last fiscal yearDec 2025
- -$65.02M-36.5% YoY
- LTMMar 2026
- -$67.05M-25.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -10.3% | — | — |
| 1 year | -36.5% | -23.8% | +12.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (65.02M) USD
- Year-over-year change
- -36.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (65.02M) | -36.5% |
| FY2024 | 2024-12-31 | (47.62M) | -17.3% |
| FY2023 | 2023-12-31 | (40.6M) | -16.1% |
| FY2022 | 2022-12-31 | (34.96M) | +56.4% |
| FY2021 | 2021-12-31 | (80.19M) | — |
EBITDA vs competitors
How CMPX compares with its peers on the latest reported figures
- CMPX's LTM Mar 2026 EBITDA of -$67.05M is the 6th highest of the 11 companies compared; the peer median is -$69.46M.
- Its year-over-year change of -25.2% is the 8th highest of 10, against a peer median of -0.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $92.9M | +159.9% | — | 939.0% | |
| LTM Mar 2026 | -$15.64M | +5.6% | — | — | |
| LTM Mar 2026 | -$17.44M | +88.7% | — | 25.0% | |
| LTM Mar 2026 | -$42.27M | -2.3% | — | — | |
| LTM Mar 2026 | -$64.18M | -19.1% | — | 1437.5% | |
| LTM Mar 2026 | -$67.05M | -25.2% | — | — | |
| LTM Mar 2026 | -$74.74M | -18129.5% | — | — | |
| LTM Dec 2025 | -$117.15M | — | — | 101.1% | |
| LTM Mar 2026 | -$163.43M | +3.9% | — | 185.2% | |
| LTM Mar 2026 | -$168.81M | -372.8% | — | 304.0% | |
| LTM Mar 2026 | -$211.5M | -0.8% | — | 333.1% | |
| Peer median (excluding CMPX) | -$69.46M | -0.8% | — | 304.0% | |
Competitors are the stored peer set for CMPX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 850K | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.47M |
| Gross Profit | 0 | 0 | 0 | 850K | (1.47M) |
| Gross Margin | — | — | — | 100.0% | — |
| Research & Development | 20.34M | 30M | 38.12M | 42.34M | 55.97M |
| Selling, General & Admin | 10.93M | 11.66M | 12.24M | 15.13M | 16.87M |
| Operating Expenses | 81.88M | 41.66M | 50.36M | 57.48M | 71.37M |
| Depreciation & Amortization | 1.62M | 1.9M | 1.89M | 1.75M | 1.47M |
| EBITDA | (80.19M) | (34.96M) | (40.6M) | (47.62M) | (65.02M) |
| EBITDA Margin | — | — | — | -5602.6% | — |
| Operating Income | (81.88M) | (41.66M) | (50.36M) | (56.63M) | (72.84M) |
| Operating Margin | — | — | — | -6661.8% | — |
| Interest Income | 29K | 2.36M | 7.9M | 7.3M | 6.35M |
| Interest Expense | 370K | 2.36M | 0 | 0 | 0 |
| Other Income / Expenses | (299K) | 2.43M | 7.87M | 7.25M | 6.35M |
| Income Before Tax | (82.18M) | (39.23M) | (42.49M) | (49.38M) | (66.49M) |
| Pre-Tax Margin | — | — | — | -5808.8% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (82.18M) | (39.23M) | (42.49M) | (49.38M) | (66.49M) |
| Net Margin | — | — | — | -5808.8% | — |
| EPS (Basic) | (1.31) | (0.35) | (0.33) | (0.36) | (0.42) |
| EPS (Diluted) | (1.31) | (0.35) | (0.33) | (0.36) | (0.42) |
| Weighted Avg Shares | 62.87M | 105.19M | 127.03M | 137.11M | 157.7M |
| Weighted Avg Shares (Diluted) | 62.87M | 105.19M | 127.03M | 137.11M | 157.7M |
Compass Therapeutics, Inc.
NASDAQ:CMPX
Intrinsic Alpha fair value
Locked
Current Price
$0.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.